



ROGEL CANCER CENTER
UNIVERSITY OF MICHIGAN HEALTH

Saturday, March 14, 2026

7:30 a.m. - 2:30 p.m.

JW Marriott, Grand Rapids and Virtual

3rd Annual

Emerging Paradigms in Liver Cancer Diagnosis and Treatment

**CME
accredited**

We are happy to host the 3rd Annual Emerging Paradigms in Liver Cancer Diagnosis and Treatment this year at the JW Marriott in Grand Rapids and virtually.

The full-day conference will focus on the full spectrum of primary liver cancers, from early detection, diagnosis, to novel cutting-edge treatments. The program will feature University of Michigan faculty members and external speakers, with ample opportunities for discussion and interactions.

At the end of this activity, medical professionals will be able to recognize which patients are appropriate for liver cancer surveillance and utilize adequate surveillance modalities to improve the early detection of hepatocellular carcinoma. Attendees will also be able to adequately risk stratify and treat hepatocellular carcinoma and cholangiocarcinoma, while also gaining an understanding of the pipeline of clinical trials for the treatment of liver cancer.

This activity is appropriate for: Medical Students, Nurse Practitioners, Nurses, Other Healthcare Professionals, Physician Assistants, Physicians

In the fields of: Gastroenterology, Hematology/Oncology, Hepatology, Medical Oncology, Other Healthcare Professions, Pathology, Radiation Oncology, Surgery, Transplant Surgery

Accreditation and Credit Designation

The University of Michigan Medical School is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Michigan Medical School designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The American Board for Transplant Certification (ABTC) has approved this educational offering for up to 5.5 Category I Continuing Education Points for Transplant Certification (CEPTCs). (Approved CEPTC Provider Number 141-71).

Agenda

7:30-7:55	Breakfast
7:55-8:00	CME Housekeeping – <i>Neehar Parikh, MD</i>
8:00-8:20	Screening for HCC – Current Evidence and Future Directions – <i>Neehar Parikh, MD</i>
8:20-8:40	Risk Factors for Cholangiocarcinoma – <i>Nataliya Razumilava, MD</i>
8:40-9:00	Endobiliary Management of Cholangiocarcinoma – <i>Allie Schulman, MD</i>
9:00-9:20	Abscopal Effects of Histotripsy: Hope or Hype – <i>Clifford Cho, MD (UM West)</i>
9:20-9:40	Locoregional Management of a Solitary HCC: What Are My Options? – <i>Jared Christensen, MD</i>
9:40-10:00	Y90 and SBRT: Advantages of Each Approach – <i>Kyle Cuneo, MD</i>
10:00-10:20	Incidence and Management of Radiation Induced Liver Disease – <i>Alisa Likhitsup, MD</i>
10:20-10:40	Break
10:40-11:10	KEYNOTE: Clinical Trial Landscape in Biliary Tract Cancers – <i>Shishir Maithel, MD (Northwestern University)</i>
11:10-11:30	Resection and Functional Liver Remnant: How Much is Too Much – <i>Christopher Sonnenday, MD</i>
11:30-11:50	Surgical Management of Colorectal Liver Metastases – <i>Ben Ferguson, MD</i>
11:50-12:25	Case Discussion
12:30-1:15	Lunch
1:15-1:35	Systemic Therapies for Patients with Impaired Liver Function – <i>Oxana Cryslar, MD</i>
1:35-1:55	The Role of NGS in Treatment Selection for Biliary Cancers – <i>Vaibhav Sahai, MBBS</i>
1:55-2:15	Management of Treatment Toxicities in Patients with Biliary Tract Cancers – <i>Aarathi Mohan, MD</i>
2:15-2:30	Q&A and Wrap Up

Registration

Cost: \$50 - physicians, \$25 - student, APPs, nurses, residents, support staff
\$7 cancellation fee; no refunds after March 5, 2026

Online: <https://michmed.org/mDYPN>

Questions: 734-936-7093

or email transplantoutreach@med.umich.edu